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ABSTRACT
Prior ﬁndings linking allergy and cancer have been inconsistent, which may be driven by diverse
assessment methods. We used serum speciﬁc immunoglobulin E (IgE) against common inhalant allergens
that was assessed prior to cancer diagnosis in studying this association. We selected 8,727 Swedish men
and women who had measurements of serum allergen-speciﬁc IgE and total IgE between 1992 and 1996.
Multivariable Cox regression using age as a timescale was performed to assess the associations of IgE
sensitization, deﬁned by any levels of serum speciﬁc IgE 35 kU/L, with risk of overall and speciﬁc cancers.
A test for trend was performed by assigning scores derived from allergen-speciﬁc IgE levels at baseline as
an ordinal scale. Kaplan–Meier curves and log-rank test were used to assess cancer survival by IgE
sensitization status. During a mean follow-up of 16 year, 689 persons were diagnosed with cancer. We
found an inverse association between IgE sensitization and cancer risk, with a hazard ratio (HR) of 0.83 and
95% conﬁdence intervals (CI) of 0.70–0.99. A similar trend was seen with speciﬁc IgE scores overall (Ptrend
D 0.007) and in women (Ptrend D 0.01). Although IgE sensitization was not associated with risk of common
site-speciﬁc cancers, serum speciﬁc IgE scores were inversely associated with melanoma risk in men and
women combined, and with risk of female breast and gynecological cancers combined. No association
with survival was observed. The association between circulating IgE levels and incident cancer may point
toward a role of T-helper 2 (TH2)-biased response in development of some cancers.
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Introduction
Allergy is a hypersensitivity reaction initiated by speciﬁc immu-
nologic mechanisms.1 Accruing evidence has indicated that
allergy may be associated with the development of cancer, and is
largely divided into two opposing views: (1) allergy may reduce
cancer risk and (2) it may increase cancer risk.2 The ﬁrst may be
explained by the immunosurveillance hypothesis, which states
that increased immune surveillance following hyper-reactive
immune responses may hinder the development of cancer.2 Sim-
ilarly, the prophylaxis hypothesis suggests that physical effects of
allergy symptoms may prevent cancer by removal of potential
carcinogens.3 The opposing hypotheses include a shift in T-
helper balance, which determines the type of immune responses
elicited. Predominance of TH2 over TH1 underlies the hypersen-
sitivity reactions in allergy, and is thought to divert immune
responses from the tumor-eradicating TH1 counterpart.
4 Addi-
tionally, allergic inﬂammation may lead to initiation and pro-
motion of cancer directly or through indirect mechanisms.5
Observational ﬁndings linking allergy and cancer are
inconclusive.6 A crude way to determine presence of allergy
would be using total IgE levels in the serum that may reﬂect
the imbalance in the immune system, but without knowing
its speciﬁcity makes the association between allergy and can-
cer challenging.7 Atopy, which refers to the genetic pre-dis-
position of developing IgE-mediated hypersensitivity or IgE
sensitization against allergens,1 is often evaluated to unpick
the role of allergy. Most previous studies crudely classiﬁed
individuals into “atopic” and “non-atopic” based on self-
reported history,8-10 which relies on an individual’s recall
and may incur a loss of time-speciﬁc information. Other
studies deﬁned atopy based on laboratory evidence, such as
the presence of circulating IgE.1 The use of serum IgE
against speciﬁc allergen provides more insight into how IgE
sensitization may be associated to cancer, but may be ham-
pered by the use of imprecise and/or different assessment
methods. Findings based on pre-cancer diagnostic levels of
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allergen-speciﬁc IgE are limited and no studies have investi-
gated the impact on cancer survival of pre-diagnostic aller-
gen-speciﬁc IgE.11-13
In the Swedish Apolipoprotein Mortality Risk Study
(AMORIS), we previously investigated the association between
total IgE and the risk of cancer in 24,820 individuals. A weak
inverse association was found albeit not statistically signiﬁcant,
and results were similar when data from our cohort was com-
bined in a meta-analysis with previous ﬁndings.7 The recently
updated AMORIS database now contains information on serum
speciﬁc IgE utilizing comparable determinations, more partici-
pants, and a longer follow-up (up to 25 y). To gain further insight
into the association between allergy and cancer, we now assessed
serum speciﬁc IgE against common inhalant allergens in relation
to risk of developing cancer and death after cancer diagnosis.
Results
Characteristics of study participants by IgE sensitization status
are shown in Table 1. The average age at baseline was 40 y, and
over half the study population were female (59%). During fol-
low-up (median: 18.6 y), 689 incident cancer cases were identi-
ﬁed. A total of 194 individuals died following cancer diagnosis,
among which 146 died from cancer. The most common three
types of cancer were prostate, female breast and colorectal can-
cers. The relative distribution of speciﬁc IgE scores to total IgE
is shown in Table S1.
We assessed cancer risk based on IgE sensitization status
and speciﬁc IgE scores as categories Table 2. When using
0.35 kU/L as the cut-off point for speciﬁc IgE, which indicates
IgE sensitization, we did not observe any association with risk
of cancer (Table 3). However, a statistically signiﬁcant inverse
trend was observed when using serum speciﬁc IgE scores in the
overall study population (Ptrend D 0.03). In sex stratiﬁcation, a
similar association was observed in women. Adjustment for
serum total IgE showed stronger associations and an inverse
association between IgE sensitization and cancer risk in the
overall population (HR: 0.83 (95% CI: 0.70–0.99). No associa-
tion was noted in men and women separately. When stratifying
the analyses by serum total IgE levels, the inverse trend was
only seen between serum allergen-speciﬁc IgE scores and can-
cer risk in the overall population and in women with total IgE
levels >100 kU/L (Table 3). Similar associations were observed
when additionally adjusting our model for the number of aller-
gen tested, the number of positive results, or the ratio between
the two (results not shown).
Similar associations to overall cancers were found when
assessing all cancers excluding NMSC (Table 4). No statistically
signiﬁcant association was found between positive IgE sensiti-
zation and risk of speciﬁc cancer types. When observing trends
across allergen-speciﬁc IgE scores, we found a lower risk of
melanoma with higher speciﬁc IgE in both men and women
combined (Ptrend D 0.04). No association was observed for
other cancer sites. To further investigate the driver of the
inverse association observed in women, we combined cancers
of female genital organs (breast and gynecological cancers) as a
single outcome and a protective effect of higher speciﬁc IgE
scores was observed (Ptrend D 0.04).
In our secondary analysis, we assessed risk of death follow-
ing cancer diagnosis. As shown by the Kaplan–Meier curves in
Fig. 1, the probability of survival was lower in men with IgE
sensitization compared to those without in the long-term fol-
low-up, but there were no statistically signiﬁcant difference
(Log-rank p > 0.05). Similarly, no differences were observed
when categories of allergen-speciﬁc IgE scores were used
(results not shown). We further evaluated this association by
conducting Cox regression and found no clear associations
between IgE sensitization or speciﬁc IgE scores and death from
all-causes or cancer, e.g. HR for cancer death was 1.04 (95% CI:
0.59–1.84) and 1.54 (0.91–2.62) for men and women with com-
pared to without IgE sensitization, respectively (results not
shown in tables).
Discussion
In the present study, IgE sensitization was associated with a
lower risk of incident cancer. The inverse trend between aller-
gen-speciﬁc IgE was more pronounced in women and among
Table 2. Speciﬁc IgE scores in CALAB and corresponding serum concentrations.
Speciﬁc IgE score Serum concentrations (kU/L) Serum IgE levels
0 <0.35 Absent/undetectable
1 0.35 – 0.70 Low level
2 0.70 – 3.50 Moderate level
3 3.50 – 17.5 High level
4 17.5 – 50 Very high level
5 50 – 100 Very high level
6 100 Very high level
Table 1. Characteristics of study participants by IgE sensitization status.
IgE sensitization
No (n D 4,714) Yes (nD 4,013)
Age (years)
Mean (SD) 42.26 (13.74) 37.31 (12.66)
Sex, male, n (%) 1661 (35.24) 1945 (48.47)
Socioeconomic status, n (%)
High 1912 (40.56) 1423 (35.46)
Low 2074 (44.00) 1697 (42.49)
Unclassiﬁed/missing 728 (15.44) 893 (22.25)
History of chronic respiratory disease, n (%) 67 (1.42) 92 (2.29)
Year of measurement, n (%)
1992–1994 1192 (25.29) 986 (24.57)
1994–1996 2682 (56.89) 1997 (49.76)
1996 840 (17.82) 1030 (25.67)
Total IgE (kU/L)
<25 1765 (37.44) 285 (7.10)
25–100 1937 (41.09) 1355 (33.77)
100 1012 (21.47) 2373 (59.13)
Mean follow-up in years, Mean (SD) 15.86 (3.59) 16.05 (3.23)
Any cancer during follow-up, n (%)
All cancer 443 (9.40) 246 (6.13)
Breast (female) 115 (2.44) 50 (1.25)
Prostate 55 (1.17) 42 (1.05)
Colorectal 43 (0.91) 21 (0.52)
Gynecological 41 (0.87) 12 (0.30)
hematological 31 (0.66) 22 (0.55)
Melanoma 27 (0.57) 10 (0.25)
Pulmonary 21 (0.45) 14 (0.35)
Bladder 14 (0.30) 11 (0.27)
NMSC 16 (0.34) 9 (0.22)
CNS 11 (0.23) 9 (0.22)
Kidney 12 (0.25) 9 (0.22)
nD number of participants.
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Table 3. Associations between IgE sensitization, serum speciﬁc IgE scores and risk of incident cancer overall and by sex with chronological age as timescale.
HR (95% CI)
IgE sensitization Speciﬁc IgE scores
n cancer/n total No Yes 0 1–2 3–4 5–6 Ptrend
Both men and women
n 4714 4013 4714 6402 8331 8727
Multivariable model 689/8727 1.0 (Ref) 0.88 (0.75–1.03) 1.0 (Ref) 1.00 (0.82–1.21) 0.74 (0.59–0.93) 0.91 (0.55–1.51) 0.03
Additional adjustment for total IgE 689/8727 1.0 (Ref) 0.83 (0.70–0.99) 1.0 (Ref) 0.95 (0.78–1.16) 0.69 (0.54–0.88) 0.79 (0.47–1.32) 0.007
Stratiﬁcation by total IgE (kU/L)
191/2050 1.0 (Ref) 0.79 (0.48–1.32) 1.0 (Ref) 0.86 (0.51–1.47) 0.48 (0.12–1.99) N/A 0.29
25–100 238/3292 1.0 (Ref) 0.85 (0.64–1.13) 1.0 (Ref) 0.91 (0.65–1.28) 0.77 (0.51–1.16) N/A 0.18
100 260/3385 1.0 (Ref) 0.82 (0.63–1.06) 1.0 (Ref) 1.00 (0.74–1.34) 0.66 (0.48–0.91) 0.81 (0.47–1.39) 0.02
Men
n 1661 1945 1661 732 1003 210
Multivariable model 277/3606 1.0 (Ref) 0.97 (0.76–1.23) 1.0 (Ref) 1.01 (0.75–1.36) 0.89 (0.65–122) 1.27 (0.64–2.52) 0.80
Additional adjustment for total IgE 277/3606 1.0 (Ref) 0.89 (0.69–1.17) 1.0 (Ref) 0.95 (0.69–1.29) 0.83 (0.59–1.16) 1.10 (0.54–2.23) 0.42
Stratiﬁcation by total IgE (kU/L)
<25 53/649 1.0 (Ref) 0.71 (0.29–1.76) 1.0 (Ref) 0.59 (0.20–1.78) 1.11 (0.27–4.67) N/A 0.64
25–100 97/1377 1.0 (Ref) 0.83 (0.54–1.28) 1.0 (Ref) 0.99 (0.59–1.66) 0.68 (0.38–1.23) N/A 0.24
100 127/1580 1.0 (Ref) 0.97 (0.67–1.41) 1.0 (Ref) 1.00 (0.64–1.57) 0.89 (0.57–1.40) 1.23 (0.58–2.61) 0.94
Women
n 3053 2068 3053 956 926 186
Multivariable model 412/5121 1.0 (Ref) 0.83 (0.67–1.03) 1.0 (Ref) 0.98 (0.76–1.27) 0.64 (0.45–0.90) 0.72 (0.34–1.53) 0.01
Additional adjustment for total IgE 412/5121 1.0 (Ref) 0.81 (0.64–1.02) 1.0 (Ref) 0.96 (0.74–1.24) 0.61 (0.42–0.87) 0.64 (0.30–1.39) 0.01
Stratiﬁcation by total IgE (kU/L)
<25 138/1401 1.0 (Ref) 0.82 (0.44–1.53) 1.0 (Ref) 0.98 (0.53–1.83) N/A N/A 0.30
25–100 141/1915 1.0 (Ref) 0.87 (0.59–1.26) 1.0 (Ref) 0.85 (0.54–1.34) 0.91 (0.52–1.58) N/A 0.51
100 133/1805 1.0 (Ref) 0.73 (0.52–1.04) 1.0 (Ref) 0.98 (0.66–1.46) 0.51 (0.31–0.83) 0.63 (0.29–1.39) 0.01
xHighest speciﬁc IgE scores recorded at baseline.
N/AD not applicable; n D number of participants.
All models were adjusted for sex (except for sex-speciﬁc analysis), socioeconomic status, period of measurement and history of chronic pulmonary disease.
Table 4. Associations between IgE sensitization, serum speciﬁc IgE scores and risk of site-speciﬁc cancers by sex with chronological age as timescale.
HR (95% CI)
IgE sensitization Speciﬁc IgE scoresx
n cancer No Yes 0 1–2 3–4 5–6 Ptrend
Both men and women
All excluding NMSC 664 1.0 (Ref) 0.82 (0.69–0.99) 1.0 (Ref) 0.96 (0.78–1.18) 0.67 (0.52–0.85) 0.81 (0.48–1.36) 0.005
Colorectal 64 1.0 (Ref) 0.71 (0.39–1.26) 1.0 (Ref) 0.75 (0.38–1.51) 0.60 (0.27–1.34) 1.23 (0.28–5.42) 0.32
hematological 53 1.0 (Ref) 0.95 (0.51–1.76) 1.0 (Ref) 1.16 (0.58–2.30) 0.66 (0.27–1.59) 1.22 (0.27–5.46) 0.62
Melanoma 37 1.0 (Ref) 0.53 (0.24–1.17) 1.0 (Ref) 0.79 (0.33–1.88) 0.32 (0.09–1.13) N/A 0.04
Pulmonary 35 1.0 (Ref) 0.87 (0.41–1.84) 1.0 (Ref) 1.24 (0.56–2.76) 0.41 (0.11–1.43) 0.94 (0.12–7.44) 0.33
Bladder 25 1.0 (Ref) 1.20 (0.50–2.87) 1.0 (Ref) 1.45 (0.56–3.77) 0.95 (0.29–3.14) N/A 0.89
NMSC 25 1.0 (Ref) 0.97 (0.40–2.39) 1.0 (Ref) 0.62 (0.17–2.20) 1.56 (0.55–4.44) N/A 0.74
Kidney 21 1.0 (Ref) 1.09 (0.40–2.95) 1.0 (Ref) 1.50 (0.52–4.30) 0.27 (0.03–2.23) 3.42 (0.63–18.50) 0.95
CNS 20 1.0 (Ref) 1.33 (0.47–3.73) 1.0 (Ref) 1.82 (0.62–5.33) 0.88 (0.21–3.61) N/A 0.74
Men
All excluding NMSC 267 1.0 (Ref) 0.89 (0.68–1.16) 1.0 (Ref) 0.95 (0.69–1.31) 0.80 (0.57–1.13) 1.12 (0.55–2.28) 0.37
Prostate 97 1.0 (Ref) 0.93 (0.38–1.04) 1.0 (Ref) 0.86 (0.50–1.48) 0.93 (0.53–1.63) 2.31 (0.78–6.82) 0.79
Colorectal 35 1.0 (Ref) 0.71 (0.34–1.49) 1.0 (Ref) 0.77 (0.31–1.88) 0.54 (0.19–1.53) 1.83 (0.38–8.77) 0.52
hematological 23 1.0 (Ref) 1.13 (0.44–2.89) 1.0 (Ref) 1.11 (0.36–3.35) 1.12 (0.35–3.62) 1.35 (0.15–12.15) 0.78
Pulmonary 15 1.0 (Ref) 1.07 (0.35–3.26) 1.0 (Ref) 1.41 (0.42–4.71) 0.57 (0.11–3.02) 2.38 (0.24–23.99) 0.93
Melanoma 12 1.0 (Ref) 0.56 (0.15–2.06) 1.0 (Ref) 0.65 (0.13–3.18) 5.31 (0.10–2.77) N/A 0.31
Women
All excluding NMSC 397 1.0 (Ref) 0.81 (0.63–1.03) 1.0 (Ref) 0.98 (0.75–1.28) 0.57 (0.39–0.83) 0.65 (0.30–1.42) 0.008
Breast and gynecological 218 1.0 (Ref) 0.76 (0.55–1.06) 1.0 (Ref) 0.85 (0.58–1.24) 0.68 (0.43–1.10) 0.36 (0.09–1.47) 0.04
Breast 165 1.0 (Ref) 0.83 (0.57–1.20) 1.0 (Ref) 0.95 (0.63–1.45) 0.69 (0.40–1.19) 0.49 (0.12–2.05) 0.14
Gynecological 53 1.0 (Ref) 0.55 (0.27–1.13) 1.0 (Ref) 0.54 (0.22–1.32) 0.65 (0.25–1.64) N/A 0.11
Colorectal 29 1.0 (Ref) 0.75 (0.29–1.91) 1.0 (Ref) 0.75 (0.25–2.26) 0.84 (0.23–3.10) N/A 0.53
Hematological 30 1.0 (Ref) 0.83 (0.37–1.88) 1.0 (Ref) 1.13 (0.48–2.71) 0.37 (0.08–1.65) 1.10 (0.14–8.82) 0.40
Melanoma 25 1.0 (Ref) 5.13 (0.19–1.42) 1.0 (Ref) 0.86 (0.30–2.43) 0.18 (0.02–1.49) N/A 0.07
xHighest speciﬁc IgE scores recorded at baseline.
N/AD not applicable; n D number of participants; NMSC D nonmelanoma skin cancer; CNS D central nervous system.
All models were adjusted for sex (except for sex-speciﬁc analysis), socioeconomic status, period of measurement, history of chronic pulmonary disease and serum total IgE.
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those with high total IgE levels. Among the most common can-
cers, no association was observed except for an inverse trend
between serum speciﬁc IgE scores and risk of melanoma in the
overall population, and with risk of breast and gynecological
cancer in women. No associations between prediagnostic aller-
gen-speciﬁc IgE and survival following cancer diagnosis were
observed.
A shift toward immunosuppressive immune responses is
characteristic of cancer.22 Nevertheless, little is known about
the role of humoral immune responses, particularly IgE, in car-
cinogenesis. IgE production and class-switch recombination
(CSR) to IgE from other immunoglobulin types such as IgG are
regulated by TH2, and it has been suggested that a biased TH2
response underlies high IgE levels in allergic individuals.23
Since only limited responses following allergen exposure are
observed for IgE,24 it is possible that any impact on carcinogen-
esis is secondary to the biased TH2 response rather than a result
of high circulating IgE itself. In support of this, a temporal
model of IgE and IgG has been proposed, in which the early-
response IgE undergo sequential CSR to higher-afﬁnity IgG3,
then to IgG1, IgG2, and ﬁnally IgG4,25-27 the latter of which
displays low immunoactivatory functions. Furthermore,
inﬂammatory TH2-biased conditions such as IL-10, IL-4,
VEGF and FoxP3C Tregs that support class switching to IgG4
rather than IgE, and elevated IgG4 levels have been reported in
different tumors including melanoma.28,29 Speciﬁcally in mela-
noma, elevated serum IgG4 levels and IgG4C B cells in patient
circulation are associated with worse clinical outcomes, imply-
ing a bias toward an alternative rather than an IgE-biased
response associated with melanoma cancer growth.30,31 Taken
together, these indications point toward a role of CSR dysregu-
lation associated with TH2-biased response in driving the link
between allergy, circulating IgE, and IgG4-related diseases
including some cancers.32 Nevertheless, our ﬁndings in individ-
uals with high total IgE (100 kU/L) may be consistent with a
potential requirement for a critical threshold toward a classical
IgE, rather than an alternative IgG4-biased TH2 immune
response activation to confer for any potential protective bene-
ﬁts from cancer.
To date, only few prospective studies have examined possible
associations between prediagnostic IgE sensitization and risk of
incident cancer. In a recent study, Skaaby and colleagues evalu-
ated serum speciﬁc evaluated IgE against inhalant allergen
among 14,849 individuals.11 A lack of association between aller-
gen-speciﬁc IgE levels and risk of overall cancer was reported for
IgE sensitization.11 Similarly, we found a lack of a statistically
signiﬁcant association when assessing IgE sensitization against
inhalant allergens in relation to overall incident cancer. How-
ever, when we took into account serum total IgE, an inverse
association was found. Differences in follow-up periods and
cohort composition may explain the discrepancy in the ﬁndings.
Our study was based on a large cohort with a median follow-up
of 18.6 y. In comparison, the study by Skaaby and colleagues
comprised ﬁve cohorts spanning over different time periods,
with a shorter overall median follow-up of 11.8 y.11 Adjustments
for other risk factors such as smoking, alcohol consumption and
physical activity did not alter ﬁndings in that study and are thus
unlikely to explain the discrepancy with the results in our study
in which risk factor information was unavailable.
For speciﬁc cancers, observational ﬁndings seem to vary by
demographics and timing of speciﬁc IgE measurements. Two
European nested case-control studies demonstrated an inverse
association between IgE sensitization against inhalant allergens
and risk of glioma in women but not men,13,33 whereas a lack
of association was reported by another nested case-control
study based on four US cohorts.34 Besides population
attributes, a smaller number of cases in the latter study may
explain this inconsistency. In case-control studies where
allergen-speciﬁc IgE in cases was assessed after diagnosis, IgE
sensitization was inversely associated with risk of lymphoid
malignancies and positively with prostate cancer risk.35,36
However, no such association was observed in nested case-
Figure 1. Kaplan–Meier curves of 10-y survival following cancer diagnosis in (A) men and (B) women based on prediagnostic IgE sensitization. Black lines indicate IgE sen-
sitization and the gray lines indicate a lack thereof.
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control studies where serum samples were prospectively
collected before diagnosis.11,12,35
In our study population, we found no associations between
IgE sensitization and risk of speciﬁc cancer sites, which is com-
parable with the study conducted by Skaaby and colleagues.11
However, an inverse association between serum speciﬁc IgE
scores and risk of breast and gynecological cancers were
observed in women. To date, evidence from observational stud-
ies on the role of allergy in these cancers remains unclear. In a
meta-analysis, a lack of associations between history of any
allergy, asthma or hay fever and breast cancer risk was sug-
gested.9 On the other hand, a reduced incidence of ovarian,
endometrial and cervical cancers have been reported in allergic
patients.37-40 There is little evidence based on IgE sensitization
status except for cancer of the uterus, where a lack of associa-
tion was suggested.11 Considering the inﬂuence of estrogen in
the development of these cancers, these results may indicate an
interplay between immunologic and hormonal factors in carci-
nogenesis. Interestingly, endocrine treatment agents for estro-
gen-positive (ERC) breast cancers such as tamoxifen has been
shown to reduce allergen-speciﬁc immunoglobulin levels
including IgE in animal models of atopic dermatitis,41 which
further suggests such complex associations.
There are several caveats in assessing serum allergen-speciﬁc
IgE as a marker of allergy. Allergen-speciﬁc IgE levels represent
the probability of having clinical allergic disease, therefore, use
of a single allergen and/or cut-off to deﬁne IgE sensitization
may not fully be representative of one’s allergic symptoms.42 In
line with this notion, we found stronger associations with cate-
gories of speciﬁc IgE compared to the conventional single cut-
off point of speciﬁc IgE levels, which indicates that speciﬁc IgE
scores or categories may be more useful than a single cut-off
point in assessing cancer risk. Additionally, it was suggested
that the number of positive inhalant allergens correlates better
with allergic diseases compared to a single positive allergen-
speciﬁc IgE test.43 In our study, we have addressed this possibil-
ity by an additional adjustment for the number of allergen
tested, the number of positive results, or the ratio between the
two, and they did not alter our ﬁndings. Finally, there is an
indication that the sum of speciﬁc IgE levels against common
inhalant allergens correlates better with clinical symptoms such
as wheezing 44 and hospitalization with asthma,45 compared to
individual levels of speciﬁc IgE. We were unable to assess
cumulative levels of speciﬁc IgE in this study. Therefore, future
studies assessing allergy-related cancer susceptibility may bene-
ﬁt from reﬁned criteria of IgE sensitization.
To date, this is the ﬁrst study documenting the association
between IgE sensitization to common inhalant allergens and the
risk of cancer using both serum allergen-speciﬁc and total IgE, and
also the ﬁrst study investigating the impact of pre-diagnostic IgE
on cancer survival. Strengths of our study include the prospectively
collected allergen-speciﬁc and total IgE levels prior to the diagnosis
of cancer. Complete follow-up was obtained and all laboratory
measurements were performed in one and the same laboratory.14
By using age as a timescale, we addressed the strong inﬂuence of
age on absolute levels of speciﬁc IgE and its relative proportion to
total IgE.19,46 A limitation of this study is the lack of information
on clinical symptoms of allergy. Although information on speciﬁc
types of allergens was available, we were unable to link individual
allergens with risk of cancer due to the lack of number of cases.
Our study population only included individuals who underwent
IgE testing as part of a check-up or as outpatients and therefore
may not be representative of the general population. However, this
is not expected to inﬂuence the internal validity of this study.
Allergy symptoms may have been confused with smoking-related
respiratory disorders. To account for the lack of information on
smoking, we adjusted our analysis for history of hospitalization
with chronic obstructive pulmonary disease and asthma. Neverthe-
less, residual confounding may still have occurred. Lastly, spurious
correlationsmay be of concern when performingmultiple compar-
isons as shown in our study. However, we planned our analyses
based on prior evidence and our results are explicable by suggested
biological pathways and ﬁndings from other studies. Therefore, the
observed association is unlikely to be spurious, although a discrep-
ancy with the strength of the true association is possible due to the
lack of cases.
In summary, our study suggests that IgE sensitization is
weakly associated with a lower risk of malignancy in cancer-free
individuals. These ﬁndings add to the evidence that immune
responses involved in allergy contribute to the susceptibility of
being diagnosed with cancer, particularly female breast and
gynecological cancers and melanoma. In particular, our results
may support a role of TH2-biased immune response in develop-
ment of these cancers, indicated by a shift in the balance between
circulating IgE and IgG subclasses including the low immunoac-
tivatory IgG4, which urges further mechanistic investigations.
Methods
Study population
The AMORIS study has been described in detail elsewhere.14
Brieﬂy, this study includes Swedish men and women with
blood samples sequentially sent to the Central Automation
Laboratory (CALAB) in Stockholm, Sweden14 Participants
were either healthy and had a laboratory testing as a part of
general health check-up, or were outpatients referred for labo-
ratory testing. None of the participants were inpatients when
samples were collected. In the AMORIS study, the CALAB
database is linked to Swedish national registries, providing
complete follow-up information on cancer diagnosis, death and
emigration.15
Following a recent update, the AMORIS study now includes
laboratory measurements of 812,073 individuals with follow-up
information until 31 December 2011. From this population, we
included 8,727 men and women aged 20 and older with no his-
tory of cancer who had baseline measurements of allergen-spe-
ciﬁc IgE against inhalant allergen and total IgE concentrations
between 1992 and 1996. The study complied with the Declara-
tion of Helsinki and was approved by the Ethics Review Board
of the Karolinska Institutet.
Assessment of outcome
Cancer diagnosis was obtained from the population-based Swedish
Cancer Register. International Classiﬁcation of Diseases, seventh
revision (ICD-7) codes were used to classify cancer sites. In addi-
tion to overall cancer (ICD-7: 140–207), we assessed all cancer
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excluding non-melanoma skin cancer (NMSC) (ICD-7: 140–207
excluding 191) and the 10 most frequently diagnosed cancers in
our study population: prostate (ICD-7: 177), female breast (ICD-7:
170), colorectal (ICD-7: 153–154), gynecological including ovarian,
uterus and cervix (ICD-7: 171–176), hematological (ICD-7: 200–
207), melanoma skin (ICD-7: 190), pulmonary (primary; ICD-7:
162), bladder (ICD-7: 181), NMSC (ICD-7: 191), central nervous
system (CNS; ICD-7: 193) and kidney cancer (ICD-7: 180). The
secondary outcomes of this study were all-cause and cancer-spe-
ciﬁc deaths. Dates and causes of death were obtained from the
Swedish Cause of Death Register, whereas information on emigra-
tion was retrieved from theMigration Register.
Assessment of exposures and covariates
Speciﬁc IgE concentrations against common inhalant allergens
were measured using immunoassay. The test system, Pharma-
cia CAP

System (Thermo Fisher Scientiﬁc, formerly Pharma-
cia Diagnostics AB, Uppsala, Sweden), is based on solid phase
coupled allergen, adsorbing the IgE antibodies in the sample
and assessed by an anti-IgE antibody commercially developed.
It has been well standardized, shows correct quantitative values
and is reproducible over time.16 A list of inhalant allergens
tested is available in Table S1. Results of allergen-speciﬁc IgE
test were expressed as scores ranging from 0 to 6 which repre-
sent different levels of IgE from undetectable up to high con-
centrations of IgE (kU/L) as displayed in Table 2. Apart from
these scores, no information on continuous levels of speciﬁc
IgE was available. As with previous studies, any scores higher
than 0 (which correspond to speciﬁc IgE levels of 0.35 kU/L)
were deﬁned as IgE sensitization and the presence of atopy.17
For consistency, the term IgE sensitization was used to describe
speciﬁc IgE levels 0.35 kU/L throughout this study. When
multiple allergens were tested at baseline, results for all aller-
gen-speciﬁc IgE measurements were collected and positive IgE
sensitization was deﬁned as having at least one positive result
among all the tested allergens. In addition to IgE sensitization
status, highest speciﬁc IgE scores recorded at baseline examina-
tions when multiple allergens were tested were used in the anal-
ysis. Serum total IgE (kU/L) was measured by enzyme-linked
immunosorbent assay (ELISA) using Immunoassay System ES
700 (Boehringer-Mannheim, Germany). Coefﬁcient of varia-
tion was less than 5%. Total IgE levels were categorized based
on the clinical cut-off points into low (<25 kU/L), moderate
(25–100 kU/L) or high levels (100 kU/L) as previously
described (173).
Age at baseline measurement (years) was collected from the
CALAB database. The period of measurement was categorized
(1992–1993, 1994–1995, 1996) to account for a long recruit-
ment period. Socioeconomic status (SES; white collar, blue col-
lar, unemployed or unknown) was based on national
Censuses.18 From the National Patient Register, we used data
on history of hospitalization with chronic pulmonary disease
including asthma (ever, never).
Statistical analysis
Multivariable Cox regression was used to estimate HR with cor-
responding 95% CI of overall risk of cancer by IgE sensitization
status (yes, no) in all participants. Follow-up time was deﬁned
as the time from baseline measurement until cancer diagnosis,
death from any cause, emigration or end of study, whichever
occurred ﬁrst. Additionally, the trend between allergen-speciﬁc
IgE scores against inhalant allergens and risk of cancer was
evaluated by assessing scores in groups (0, 1–2, 3–4, 5–6) as an
ordinal scale. Levels of allergen-speciﬁc IgE are known to sub-
stantially decrease with age.19 Therefore, all analyses were per-
formed using age as the time scale with delayed entry.
Models were adjusted for sex, SES, and period of measure-
ment, history of chronic pulmonary disease to account for
asthma and as a proxy for smoking given their association to
IgE sensitivity and risk of lung cancer.20,21 Analyses were
repeated in men and women separately. A further adjustment
for categories of total IgE levels was performed in the second
model. To evaluate any effect modiﬁcation by total IgE levels,
analyses were stratiﬁed according to total IgE levels. In an addi-
tional analysis, we adjusted our model for the number of aller-
gen tested, the number of positive results or the ratio between
the two. Analysis was subsequently performed for all cancer
excluding NMSC and the 10 most common cancer sites with
adjustment for total IgE levels. We repeated a similar analysis
in men and women but only assessed the ﬁve sex-speciﬁc most
common cancer sites due to the lack of number of cases.
For our secondary objective, we studied pre-diagnostic aller-
gen-speciﬁc IgE in relation to survival after cancer diagnosis.
Three cancer patients were excluded in the analysis because the
diagnosis of cancer occurred at the time of death, leaving 686
individuals with cancer in the ﬁnal analysis. Follow-up time
was deﬁned as the time from cancer diagnosis until death from
any cause, emigration or end of study, whichever occurred ﬁrst.
Kaplan–Meier curves were used to assess overall survival by
IgE sensitization status and scores of allergen-speciﬁc IgE, and
statistical differences were assessed with the log-rank test. Cox
regression was used to quantify the risks of all-cause and can-
cer-speciﬁc deaths by IgE sensitization status and allergen-spe-
ciﬁc IgE scores with age at diagnosis as time scale. The models
were adjusted for the interval between baseline IgE measure-
ments and cancer diagnosis, and total IgE levels.
All analyses were conducted with Statistical Analysis Soft-
ware (SAS) release 9.4 (SAS Institute, Cary, NC) and R version
3.0.2 (R Foundation for Statistical Computing).
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